Longwood Capital Partners »

Maze Therapeatics shares owned by Longwood Capital Partners

Quarter-by-quarter ownership of Maze Therapeatics (MAZE) shares owned by Longwood Capital Partners from 13F filings

Historical chart of Longwood Capital Partners investment in Maze Therapeatics

Tip: Access up to 7 years of quarterly data

All positions including Maze Therapeatics held by Longwood Capital Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Maze Therapeatics by Longwood Capital Partners

Quarter filed Position value Share count Share price at filing
2025-12-31 $829k 20k 41.43

More positions owned by Longwood Capital Partners

Terns Pharmaceuticals (TERN)
Praxis Precision Medicines I (PRAX)
Cidara Therapeutics Com New (CDTX)
Ocular Therapeutix (OCUL)
Aadi Bioscience (WHWK)
Bright Minds Biosciences Com New (DRUG)
Compass Therapeutics (CMPX)
Jazz Pharmaceuticals Shs Usd (JAZZ)
Insmed Com Par $.01 (INSM)
Argen Se - Sponsored Adr (ARGX)
Surrozen Com New (SRZN)
Amylyx Pharmaceuticals (AMLX)
Minerva Neurosciences Com New (NERV)
Tango Therapeutics (TNGX)
Taysha Gene Therapies Com Shs (TSHA)

View all positions for Longwood Capital Partners

Top funds holding Maze Therapeatics

Frazier Life Sciences Management
Trv Gp Iv
Deep Track Capital
Arch Venture Corp
BlackRock
AH Capital Management
Vanguard Group
VR Adviser
Alphabet
General Catalyst Group Management
Woodline Partners
TRV GP V
Logos Global Management
Bellevue Group
Marshall Wace

View all funds holding Maze Therapeatics